MedTrace Logo

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

NCT01221818 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2014-07-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of single oral ascending doses of E6007 in healthy subjects.

Conditions

Interventions

DRUG

E6007

E6007 25mg single dose or matching placebo

DRUG

E6007

E6007 50mg single dose or matching placebo

DRUG

E6007

E6007 100mg single dose or matching placebo

DRUG

E6007

E6007 200mg single dose or matching placebo

DRUG

E6007

E6007 400mg single dose or matching placebo

DRUG

E6007

E6007 600 mg single dose or matching placebo

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Gina Pastino · Eisai Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01221818 on ClinicalTrials.gov